קלרידקס

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

CLARITHROMYCIN

Disponibbli minn:

DEXCEL LTD, ISRAEL

Kodiċi ATC:

J01FA09

Għamla farmaċewtika:

קפליות

Kompożizzjoni:

CLARITHROMYCIN 250 MG

Rotta amministrattiva:

פומי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

DEXCEL LTD, ISRAEL

Grupp terapewtiku:

CLARITHROMYCIN

Żona terapewtika:

CLARITHROMYCIN

Indikazzjonijiet terapewtiċi:

Klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. Upper respiratory tract infections, for example, sinusitis and pharyngitis. Klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. Klaridex is also indicated in combination with proton pump inhibitor for the eradication of H. Pylori in patients with proven duodenal ulcer. Treatment of Mycobacterium Avium Complex infection in AIDS patients.

Data ta 'l-awtorizzazzjoni:

2014-05-31